• Explore /
  • Poster
  • / Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Sumit Kumar Subudhi

The University of Texas MD Anderson Cancer Center, Houston, TX

Bilal A. Siddiqui , Joseph J. Maly , Lakshminarayanan Nandagopal , Elaine Tat Lam , Young E. Whang , Mukul Minocha , Vinita Gupta , Xianne Penny , Freda Cooner , Camila Jhones , Andrew Paluch , Mark Salvati , Margit Janat-Amsbury , Tobias Eggert , Hosein Kouros-Mehr , Anthony M. Joshua , Rahul Raj Aggarwal , Johann S. De Bono , Sumit Kumar Subudhi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04631601

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5088)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5088

Abstract #

TPS5088

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Edwin M. Posadas

First Author: Elena Castro

First Author: Karim Fizazi

First Author: Vincenzo Gennusa